1
|
Storebø OJ, Ribeiro JP, Kongerslev MT, Stoffers-Winterling J, Sedoc Jørgensen M, Lieb K, Bateman A, Kirubakaran R, Dérian N, Karyotaki E, Cuijpers P, Simonsen E. Individual participant data systematic reviews with meta-analyses of psychotherapies for borderline personality disorder. BMJ Open 2021; 11:e047416. [PMID: 34155077 PMCID: PMC8217922 DOI: 10.1136/bmjopen-2020-047416] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
INTRODUCTION The heterogeneity in people with borderline personality disorder (BPD) and the range of specialised psychotherapies means that people with certain BPD characteristics might benefit more or less from different types of psychotherapy. Identifying moderating characteristics of individuals is a key to refine and tailor standard treatments so they match the specificities of the individual participant. The objective of this is to improve the quality of care and the individual outcomes. We will do so by performing three systematic reviews with meta-analyses of individual participant data (IPD). The aim of these reviews is to investigate potential predictors and moderating patient characteristics on treatment outcomes for patients with BPD. METHODS AND ANALYSIS We performed comprehensive searches in 22 databases and trial registries up to October 6th 2020. These will be updated with a top-up search up until June 2021. Our primary meta-analytic method will be the one-stage random-effects approach. To identify predictors, we will use the one-stage model that accounts for interaction between covariates and treatment allocation. Heterogeneity in case-mix will be assessed with a membership model based on a multinomial logistic regression where study membership is the outcome. A random-effects meta-analysis is chosen to account for expected levels of heterogeneity. ETHICS AND DISSEMINATION The statistical analyses will be conducted on anonymised data that have already been approved by the respective ethical committees that originally assessed the included trials. The three IPD reviews will be published in high-impact factor journals and their results will be presented at international conferences and national seminars. PROSPERO REGISTRATION NUMBER CRD42021210688.
Collapse
Affiliation(s)
- Ole Jakob Storebø
- Psychiatric Department, Region Zealand Psychiatry, Psychiatric Research Unit, Slagelse, Denmark
- Department of Psychology, University of Southern Denmark Faculty of Health Sciences, Odense, Denmark
| | - Johanne Pereira Ribeiro
- Psychiatric Department, Region Zealand Psychiatry, Psychiatric Research Unit, Slagelse, Denmark
| | | | - Jutta Stoffers-Winterling
- Department of Psychiatry and Psychotherapy, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Rheinland-Pfalz, Germany
| | - Mie Sedoc Jørgensen
- Psychiatric Department, Region Zealand Psychiatry, Psychiatric Research Unit, Slagelse, Denmark
| | - Klaus Lieb
- Psychiatry and Psychotherapy, University Medical Center Mainz, Mainz, Germany
| | - Anthony Bateman
- Royal Free and University College Medical School, London, UK
- Halliwick Day Unit, St. Ann's Hospital, London, UK
| | - Richard Kirubakaran
- Prof BV Moses Centre for Evidence-Informed Healthcare and Health Policy, Vellore, India
| | - Nicolas Dérian
- Data and Development Support Unit, Region Zealand, Køge, Denmark
| | - Eirini Karyotaki
- Department of Clinical Psychology, VU University Amsterdam, Amsterdam, The Netherlands
| | - Pim Cuijpers
- Department of Clinical Psychology, VU University Amsterdam, Amsterdam, The Netherlands
| | - Erik Simonsen
- Psychiatric Department, Region Zealand Psychiatry, Psychiatric Research Unit, Slagelse, Denmark
| |
Collapse
|
2
|
Choudhary S, Pradhan D, Pandey A, Khan MK, Lall R, Ramesh V, Puri P, Jain AK, Thomas G. The Association of Metabolic Syndrome and Psoriasis: A Systematic Review and Meta-Analysis of Observational Study. Endocr Metab Immune Disord Drug Targets 2020; 20:703-717. [DOI: 10.2174/1871530319666191008170409] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/07/2019] [Revised: 09/14/2019] [Accepted: 09/16/2019] [Indexed: 02/06/2023]
Abstract
Background:
Metabolic syndrome worsens complications in psoriasis patients by predisposing
them to cardiovascular diseases. Psoriasis has been widely associated with metabolic syndrome;
however, it has still not been proven owing to a limited number of studies and some of those reporting
conflicting results.
Objective:
Psoriasis has reportedly been associated with metabolic syndrome; however, it has yet not
been established beyond doubt owing to conflicting literature. The present meta-analysis of observational
studies aims to evaluate the prevalence of metabolic syndrome in psoriasis patients and establish
an inferring point that psoriasis patients are certainly susceptible to metabolic syndrome. The study
will benefit clinicians to assess and monitor psoriasis patients for several associated comorbid conditions
and in its treatment.
Methods:
A systematic web search for ‘Psoriasis’, ‘Metabolic Syndrome’, ‘Hypertension’, ‘Plasma
Glucose’, ‘Dyslipidaemia’, ‘Waist Circumference’ was performed, collecting all original observational
studies on humans up to April 30, 2018. Depending on the inclusion and exclusion criteria, articles
were screened for eligibility. Due to the presence of significant heterogeneity, the Odds Ratio (OR)
was calculated using a random-effect model with Der-Simonian and Laird method. The statistical heterogeneity
was determined using I2 statistics. Comprehensive Meta-Analysis Software, Version 3 was
used to perform all the analysis.
Results:
Sixty-three studies encompassing 15,939 psoriasis patients and 103,984 controls were included
in this meta-analysis. Among them, 30.29 % of psoriasis patients were reported with metabolic
syndrome in comparison to 21.70 % of subjects in the control group. The present study clearly indicates
an increased prevalence of metabolic syndrome among psoriasis patients (OR: 2.077 [95% CI,
1.84 - 2.34]).
Conclusions:
The findings support the fact that psoriasis patients have a higher incidence of metabolic
syndrome. Our study also recommends that psoriasis patients should be regularly monitored for metabolic
syndrome complications and its associated risk factors such as hypertension, raised triglyceride,
lowered HDL Cholesterol, increased fasting plasma glucose, and waist circumference.
Collapse
Affiliation(s)
- Saumya Choudhary
- Department of Molecular and Cellular Engineering, Sam Higginbottom University of Agriculture, Technology and Sciences, Allahabad, India
| | - Dibyabhaba Pradhan
- Computational Genomics Centre, Informatics, Systems and Research Management (ISRM) Division- Indian Council of Medical Research, New Delhi, India
| | - Anamika Pandey
- Department of Soil Science and Plant Nutrition, Selcuk University, Turkey
| | - Mohd. Kamran Khan
- Department of Soil Science and Plant Nutrition, Selcuk University, Turkey
| | - Rohit Lall
- Department of Molecular and Cellular Engineering, Sam Higginbottom University of Agriculture, Technology and Sciences, Allahabad, India
| | - V. Ramesh
- Department of Skin and STD, Vardhman Mahavir Medical College, Safdarjung Hospital, New Delhi, India
| | - Poonam Puri
- Department of Skin and STD, Vardhman Mahavir Medical College, Safdarjung Hospital, New Delhi, India
| | - Arun K. Jain
- Biomedical Informatics Centre, National Institute of Pathology - Indian Council of Medical Research, New Delhi, India
| | - George Thomas
- Department of Molecular and Cellular Engineering, Sam Higginbottom University of Agriculture, Technology and Sciences, Allahabad, India
| |
Collapse
|
3
|
Pufulete M, Maishman R, Dabner L, Higgins JPT, Rogers CA, Dayer M, MacLeod J, Purdy S, Hollingworth W, Schou M, Anguita-Sanchez M, Karlström P, Shochat MK, McDonagh T, Nightingale AK, Reeves BC. B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data. Syst Rev 2018; 7:112. [PMID: 30064502 PMCID: PMC6069819 DOI: 10.1186/s13643-018-0776-8] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/09/2018] [Accepted: 07/16/2018] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND We estimated the effectiveness of serial B-type natriuretic peptide (BNP) blood testing to guide up-titration of medication compared with symptom-guided up-titration of medication in patients with heart failure (HF). METHODS Systematic review and meta-analysis of randomised controlled trials (RCTs). We searched: MEDLINE (Ovid) 1950 to 9/06/2016; Embase (Ovid), 1980 to 2016 week 23; the Cochrane Library; ISI Web of Science (Citations Index and Conference Proceedings). The primary outcome was all-cause mortality; secondary outcomes were death related to HF, cardiovascular death, all-cause hospital admission, hospital admission for HF, adverse events, and quality of life. IPD were sought from all RCTs identified. Random-effects meta-analyses (two-stage) were used to estimate hazard ratios (HR) and confidence intervals (CIs) across RCTs, including HR estimates from published reports of studies that did not provide IPD. We estimated treatment-by-covariate interactions for age, gender, New York Heart Association (NYHA) class, HF type; diabetes status and baseline BNP subgroups. Dichotomous outcomes were analysed using random-effects odds ratio (OR) with 95% CI. RESULTS We identified 14 eligible RCTs, five providing IPD. BNP-guided therapy reduced the hazard of hospital admission for HF by 19% (13 RCTs, HR 0.81, 95% CI 0.68 to 0.98) but not all-cause mortality (13 RCTs; HR 0.87, 95% CI 0.75 to 1.01) or cardiovascular mortality (5 RCTs; OR 0.88, 95% CI 0.67 to 1.16). For all-cause mortality, there was a significant interaction between treatment strategy and age (p = 0.034, 11 RCTs; HR 0.70, 95% CI 0.53-0.92, patients < 75 years old and HR 1.07, 95% CI 0.84-1.37, patients ≥ 75 years old); ejection fraction (p = 0.026, 11 RCTs; HR 0.84, 95% CI 0.71-0.99, patients with heart failure with reduced ejection fraction (HFrEF); and HR 1.33, 95% CI 0.83-2.11, patients with heart failure with preserved ejection fraction (HFpEF)). Adverse events were significantly more frequent with BNP-guided therapy vs. symptom-guided therapy (5 RCTs; OR 1.29, 95% CI 1.04 to 1.60). CONCLUSION BNP-guided therapy did not reduce mortality but reduced HF hospitalisation. The overall quality of the evidence varied from low to very low. The relevance of these findings to unselected patients, particularly those managed by community generalists, are unclear. SYSTEMATIC REVIEW REGISTRATION PROSPERO CRD42013005335.
Collapse
Affiliation(s)
- Maria Pufulete
- Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Level 7, Bristol Royal Infirmary, Queen's Building, Bristol, BS2 8HW, UK.
| | - Rachel Maishman
- Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Level 7, Bristol Royal Infirmary, Queen's Building, Bristol, BS2 8HW, UK
| | - Lucy Dabner
- Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Level 7, Bristol Royal Infirmary, Queen's Building, Bristol, BS2 8HW, UK
| | - Julian P T Higgins
- School of Social and Community Medicine, University of Bristol, Bristol, UK
| | - Chris A Rogers
- Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Level 7, Bristol Royal Infirmary, Queen's Building, Bristol, BS2 8HW, UK
| | - Mark Dayer
- Department of Cardiology, Taunton and Somerset NHS Foundation Trust, Taunton, UK
| | - John MacLeod
- School of Social and Community Medicine, University of Bristol, Bristol, UK
| | - Sarah Purdy
- School of Social and Community Medicine, University of Bristol, Bristol, UK
| | | | - Morten Schou
- Herlev and Gentofte University Hospital, Herlev, DK-2730, Copenhagen, Denmark
| | | | - Patric Karlström
- Division of Cardiology, Department of Medicine, County Hospital Ryhov, Jönköping, Sweden
| | | | - Theresa McDonagh
- Cardiovascular Division, King's College Hospital, King's College London, Denmark Hill, London, SE5 9RS, UK
| | - Angus K Nightingale
- Department of Cardiology, Bristol Heart Institute, Bristol Royal Infirmary, Bristol, BS2 8HW, UK
| | - Barnaby C Reeves
- Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Level 7, Bristol Royal Infirmary, Queen's Building, Bristol, BS2 8HW, UK
| |
Collapse
|
4
|
Pufulete M, Maishman R, Dabner L, Mohiuddin S, Hollingworth W, Rogers CA, Higgins J, Dayer M, Macleod J, Purdy S, McDonagh T, Nightingale A, Williams R, Reeves BC. Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model. Health Technol Assess 2018; 21:1-150. [PMID: 28774374 DOI: 10.3310/hta21400] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Heart failure (HF) affects around 500,000 people in the UK. HF medications are frequently underprescribed and B-type natriuretic peptide (BNP)-guided therapy may help to optimise treatment. OBJECTIVE To evaluate the clinical effectiveness and cost-effectiveness of BNP-guided therapy compared with symptom-guided therapy in HF patients. DESIGN Systematic review, cohort study and cost-effectiveness model. SETTING A literature review and usual care in the NHS. PARTICIPANTS (a) HF patients in randomised controlled trials (RCTs) of BNP-guided therapy; and (b) patients having usual care for HF in the NHS. INTERVENTIONS Systematic review: BNP-guided therapy or symptom-guided therapy in primary or secondary care. Cohort study: BNP monitored (≥ 6 months' follow-up and three or more BNP tests and two or more tests per year), BNP tested (≥ 1 tests but not BNP monitored) or never tested. Cost-effectiveness model: BNP-guided therapy in specialist clinics. MAIN OUTCOME MEASURES Mortality, hospital admission (all cause and HF related) and adverse events; and quality-adjusted life-years (QALYs) for the cost-effectiveness model. DATA SOURCES Systematic review: Individual participant or aggregate data from eligible RCTs. Cohort study: The Clinical Practice Research Datalink, Hospital Episode Statistics and National Heart Failure Audit (NHFA). REVIEW METHODS A systematic literature search (five databases, trial registries, grey literature and reference lists of publications) for published and unpublished RCTs. RESULTS Five RCTs contributed individual participant data (IPD) and eight RCTs contributed aggregate data (1536 participants were randomised to BNP-guided therapy and 1538 participants were randomised to symptom-guided therapy). For all-cause mortality, the hazard ratio (HR) for BNP-guided therapy was 0.87 [95% confidence interval (CI) 0.73 to 1.04]. Patients who were aged < 75 years or who had heart failure with a reduced ejection fraction (HFrEF) received the most benefit [interactions (p = 0.03): < 75 years vs. ≥ 75 years: HR 0.70 (95% CI 0.53 to 0.92) vs. 1.07 (95% CI 0.84 to 1.37); HFrEF vs. heart failure with a preserved ejection fraction (HFpEF): HR 0.83 (95% CI 0.68 to 1.01) vs. 1.33 (95% CI 0.83 to 2.11)]. In the cohort study, incident HF patients (1 April 2005-31 March 2013) were never tested (n = 13,632), BNP tested (n = 3392) or BNP monitored (n = 71). Median survival was 5 years; all-cause mortality was 141.5 out of 1000 person-years (95% CI 138.5 to 144.6 person-years). All-cause mortality and hospital admission rate were highest in the BNP-monitored group, and median survival among 130,433 NHFA patients (1 January 2007-1 March 2013) was 2.2 years. The admission rate was 1.1 patients per year (interquartile range 0.5-3.5 patients). In the cost-effectiveness model, in patients aged < 75 years with HFrEF or HFpEF, BNP-guided therapy improves median survival (7.98 vs. 6.46 years) with a small QALY gain (5.68 vs. 5.02) but higher lifetime costs (£64,777 vs. £58,139). BNP-guided therapy is cost-effective at a threshold of £20,000 per QALY. LIMITATIONS The limitations of the trial were a lack of IPD for most RCTs and heterogeneous interventions; the inability to identify BNP monitoring confidently, to determine medication doses or to distinguish between HFrEF and HFpEF; the use of a simplified two-state Markov model; a focus on health service costs and a paucity of data on HFpEF patients aged < 75 years and HFrEF patients aged ≥ 75 years. CONCLUSIONS The efficacy of BNP-guided therapy in specialist HF clinics is uncertain. If efficacious, it would be cost-effective for patients aged < 75 years with HFrEF. The evidence reviewed may not apply in the UK because care is delivered differently. FUTURE WORK Identify an optimal BNP-monitoring strategy and how to optimise HF management in accordance with guidelines; update the IPD meta-analysis to include the Guiding Evidence Based Therapy Using Biomarker Intensified Treatment (GUIDE-IT) RCT; collect routine long-term outcome data for completed and ongoing RCTs. TRIAL REGISTRATION Current Controlled Trials ISRCTN37248047 and PROSPERO CRD42013005335. FUNDING This project was funded by the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 40. See the NIHR Journals Library website for further project information. The British Heart Foundation paid for Chris A Rogers' and Maria Pufulete's time contributing to the study. Syed Mohiuddin's time is supported by the NIHR Collaboration for Leadership in Applied Health Research and Care West at University Hospitals Bristol NHS Foundation Trust. Rachel Maishman contributed to the study when she was in receipt of a NIHR Methodology Research Fellowship.
Collapse
Affiliation(s)
- Maria Pufulete
- Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Bristol, UK
| | - Rachel Maishman
- Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Bristol, UK
| | - Lucy Dabner
- Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Bristol, UK
| | - Syed Mohiuddin
- School of Social and Community Medicine, University of Bristol, Bristol, UK
| | | | - Chris A Rogers
- Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Bristol, UK
| | - Julian Higgins
- School of Social and Community Medicine, University of Bristol, Bristol, UK
| | - Mark Dayer
- Department of Cardiology, Taunton and Somerset NHS Foundation Trust, Taunton, UK
| | - John Macleod
- School of Social and Community Medicine, University of Bristol, Bristol, UK
| | - Sarah Purdy
- School of Social and Community Medicine, University of Bristol, Bristol, UK
| | - Theresa McDonagh
- Cardiovascular Division, King's College London, King's College Hospital, London, UK
| | - Angus Nightingale
- Department of Cardiology, Bristol Heart Institute, Bristol Royal Infirmary, Bristol, UK
| | - Rachael Williams
- Clinical Practice Research Datalink, Medicines and Healthcare products Regulatory Agency, London, UK
| | - Barnaby C Reeves
- Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Bristol, UK
| |
Collapse
|
5
|
Hollingworth W, Biswas M, Maishman RL, Dayer MJ, McDonagh T, Purdy S, Reeves BC, Rogers CA, Williams R, Pufulete M. The healthcare costs of heart failure during the last five years of life: A retrospective cohort study. Int J Cardiol 2016; 224:132-138. [PMID: 27648982 DOI: 10.1016/j.ijcard.2016.09.021] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/17/2016] [Revised: 08/22/2016] [Accepted: 09/12/2016] [Indexed: 10/21/2022]
Abstract
BACKGROUND Evidence on the economic impact of heart failure (HF) is vital in order to predict the cost-effectiveness of novel interventions. We estimate the health system costs of HF during the last five years of life. METHODS We used linked primary care and mortality data accessed through the Clinical Practice Research Datalink (CPRD) to identify 1555 adults in England who died with HF in 2012/13. We used CPRD and linked Hospital Episode Statistics to estimate the cost of medications, primary and hospital healthcare. Using GLS regression we estimated the relationship between costs, HF diagnosis, proximity to death and patient characteristics. RESULTS In the last 3months of life, healthcare costs were £8827 (95% CI £8357 to £9296) per patient, more than 90% of which were for inpatient or critical care. In the last 3months, patients spent on average 17.8 (95% CI 16.8 to 18.8) days in hospital and had 8.8 (95% CI 8.4 to 9.1) primary care consultations. Most (931/1555; 59.9%) patients were in hospital on the day of death. Mean quarterly healthcare costs in quarters after HF diagnosis were higher (£1439; [95% CI £1260 to £1619]) than in quarters preceding diagnosis. Older patients and patients with lower comorbidity scores had lower costs. CONCLUSIONS Healthcare costs increase sharply at the end of life and are dominated by hospital care. There is potential to save money by implementation and evaluation of interventions that are known to reduce hospitalisations for HF, particularly at the end of life.
Collapse
Affiliation(s)
| | - Mousumi Biswas
- School of Social and Community Medicine, University of Bristol, Bristol, UK
| | - Rachel L Maishman
- Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Bristol, UK
| | - Mark J Dayer
- Department of Cardiology, Taunton and Somerset NHS Foundation Trust, Taunton, UK
| | | | - Sarah Purdy
- School of Social and Community Medicine, University of Bristol, Bristol, UK
| | - Barnaby C Reeves
- Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Bristol, UK
| | - Chris A Rogers
- Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Bristol, UK
| | - Rachael Williams
- Clinical Practice Research Datalink, Medicines and Healthcare products Regulatory Agency, London, UK
| | - Maria Pufulete
- Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Bristol, UK
| |
Collapse
|
6
|
Yellareddygari SKR, Pasche JS, Taylor RJ, Gudmestad NC. Individual Participant Data Meta-Analysis of Foliar Fungicides Applied for Potato Early Blight Management. PLANT DISEASE 2016; 100:200-206. [PMID: 30688582 DOI: 10.1094/pdis-05-15-0530-re] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Foliar fungicides continue to be the primary means of early blight management on potato in the United States. Both premium-priced, single-site mode-of-action "specialty" fungicides and standard protectant multisite fungicides are applied, either alone or incorporated into fungicide rotation programs to combat early blight. Individual participant data meta-analysis was conducted to compare overall fungicide efficacy against early blight on potato, quantify tuber yields, and identify the most efficacious timing for fungicide applications. In this study, the specialty fungicide-based applications were compared against the standard fungicides chlorothalonil and mancozeb applied alone. Type 3 fixed effects indicated that there was a significant difference (P < 0.0001) in overall efficacy and yield among the treatments applied to manage early blight in potato. There was a significant difference (P < 0.0001) among treatments in early blight development during the growing season. Applications incorporating specialty fungicides, when compared with standard fungicides, significantly affected disease severity from vegetative growth initiation (P = 0.0139) to tuber maturation (P = 0.0009). Results demonstrate that the higher cost, specialty-fungicide-based applications were most effective for early blight management in North Dakota and Minnesota.
Collapse
Affiliation(s)
| | - Julie S Pasche
- Department of Plant Pathology, North Dakota State University, Fargo 58105
| | - Raymond J Taylor
- Department of Plant Pathology, North Dakota State University, Fargo 58105
| | - Neil C Gudmestad
- Department of Plant Pathology, North Dakota State University, Fargo 58105
| |
Collapse
|
7
|
Cheng N, Wang H, Dong J, Pan S, Wang X, Han Y, Han Y, Yang R. Elevated serum brain natriuretic peptide and matrix metalloproteinases 2 and 9 in Wilson's disease. Metab Brain Dis 2015; 30:1087-91. [PMID: 26077744 DOI: 10.1007/s11011-015-9685-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/16/2014] [Accepted: 05/15/2015] [Indexed: 01/17/2023]
Abstract
Wilson's disease (WD) is a disease of copper metabolism characterized by excessive copper deposition in the body. It is reported abnormal copper metabolism has been associated with cardiovascular disease. BNP and MMP2/9 were biomarkers of congestive heart failure (CHF). There is rare study to explore whether serum concentrations of BNP, MMP2, and or MMP9 are altered in patients with WD. In this study we determine whether serum concentrations of brain natriuretic peptide (BNP) and matrix metalloproteinases (MMP) 2 and 9 are increased in patients with WD. Serum BNP, MMP2 and MMP9 were measured by an ELISA in 34 patients with hepatic WD, in 68 patients with neurological WD, and in 33 healthy controls. We found serum BNP levels were higher in patients with neurological WD than in healthy controls (p = 0.033). Serum MMP2 levels were higher in patients with hepatic (p = 0.009) and neurologic (p = 0.0004) WD than in controls. Serum MMP9 levels were higher in patients with neurologic WD than in patients with hepatic WD (p = 0.002) and controls (p = 0.00005), and were higher in patients with hepatic WD than in controls (p = 0.03). Serum BNP levels were negatively correlated with ceruloplasmin (p = 0.017, r = -0.215), while serum (p = 0.019, r = -0.221) and MMP9 (p = 0.011, r = -0.231) in patients with WD were negatively correlated with ceruloplasmin. BNP, MMP2, and MMP9 may reflect the deposition of copper in the heart.
Collapse
Affiliation(s)
- Nan Cheng
- Wilson Disease Centre, Hospital Affiliated to Anhui Chinese Medical University, No. 357, Changjiangzhong Road, Hefei, Anhui, China
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Shao M, Huang C, Li Z, Yang H, Feng Q. Effects of glutamine and valsartan on the brain natriuretic peptide and N-terminal pro-B-type natriuretic peptide of patients with chronic heart failure. Pak J Med Sci 2015; 31:82-6. [PMID: 25878619 PMCID: PMC4386162 DOI: 10.12669/pjms.311.6302] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2014] [Revised: 09/18/2014] [Accepted: 10/03/2014] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To analyze the effects of glutamine and valsartan on the brain natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) of patients with chronic heart failure (CHF). METHODS A total of 140 CHF patients were divided into a treatment group and a control group by random drawing, and were subjected to standard anti-heart failure treatment and administered with valsartan. Besides, the treatment group was also intravenously transfused glutamine. The treatment lasted eight weeks. RESULTS The overall efficacy of treatment group and control group were 98.6% and 90.0% respectively, with a statistically significant difference (P<0.05). The two groups had significantly increased left ventricular ejection fractions as well as significantly decreased left ventricular end-diastolic volumes and left ventricular end-diastolic dimensions after treatments (P<0.05) compared with those before. There were also inter-group differences between these values (P<0.05). After treatment, the levels of BNP, NT-proBNP and CD8(+) in both groups significantly decreased (P<0.05), whereas those of CD4(+) significantly increased (P<0.05). The two groups also had significantly different values (P<0.05). CONCLUSION Glutamine in combination with valsartan enhanced the therapeutic effects by improving cardiac function, which may be associated with decreased expressions of BNP and NT-proBNP and beneficial effects of glutamine on immune function.
Collapse
Affiliation(s)
- Mingliang Shao
- Dr. Mingliang Shao, Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute of Wuhan University, Wuhan, People's Republic of China
| | - Congxin Huang
- Dr. Congxin Huang, Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute of Wuhan University, Wuhan, People's Republic of China
| | - Zhen Li
- Dr. Zhen Li, Department of Cardiology, Renmin Hospital of Xuancheng City, Xuancheng, People's Republic of China
| | - Hui Yang
- Dr. Hui Yang, Department of Cardiology, Renmin Hospital of Xuancheng City, Xuancheng, People's Republic of China
| | - Qifan Feng
- Dr. Qifan Feng, Department of Cardiology, Renmin Hospital of Xuancheng City, Xuancheng, People's Republic of China
| |
Collapse
|
9
|
Tang Y, Lu W, Zhang Z, Zuo P, Ma G. Hypersplenism: an independent risk factor for myocardial remodeling in chronic heart failure patients. Int J Clin Exp Med 2015; 8:5197-5206. [PMID: 26131093 PMCID: PMC4483994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2014] [Accepted: 03/26/2015] [Indexed: 06/04/2023]
Abstract
BACKGROUND During the progression of chronic heart failure (CHF), decreased cardiac functioning is often associated with congestion in the inferior vena vein, which in turn induces splenomegaly and subsequent hypersplenism. Hypersplenism has been shown to exacerbate endothelial dysfunction and adverse cardiac remodeling in HF mice. However, it is unknown whether this effect also occurs in CHF patients with hypersplenism. Here, we compared different patterns of myocardial remodeling between patients with and without hypersplenism. METHODS 33 CHF patients with hypersplenism were selected and carefully examined. Clinical data and baseline hemogram measurements were included in the evaluation. Another 35 CHF patients were randomly chosen as controls. All patients received formal HF treatment to ameliorate their symptoms and to preserve heart structure and functioning. Peripheral blood-derived endothelial progenitor cells (EPCs) were cultured, and the experimenters were blinded to the patients' clinical characteristics. The biological properties of the cells were then compared. The groups were also compared in terms of the free plasma hemoglobin and heme levels, endothelial adhesion molecule expression, left ventricular ejection fraction (LvEF) and cardiovascular events (re-PCI, re-myocardial infarction, stent thrombosis, stroke and death due to cardiovascular or vascular causes). RESULTS The free plasma hemoglobin and heme levels were significantly higher in the CHF patients with hypersplenism compared with the controls (P<0.001). Additionally, the CHF patients with hypersplenism had increased levels of VCAM-1, ICAM-1, P-selectin and E-selectin (P<0.001). Echocardiography revealed a significant reduction in the LVEF in these patients compared with the controls at the 24(th) month (P=0.013). During a mean follow-up period of 24±1 months, cardiovascular events were observed in 16 patients in the CHF with hypersplenism group and 9 patients in the control group. Univariate Kaplan-Meier analysis further revealed a significant difference between the groups (P=0.021). The mRNA levels of endothelial NO synthase enzyme (eNOS) in EPCs from the CHF patients with hypersplenism were significantly lower than those in the control subjects (P<0.001). We also observed decreased proliferation potential of EPCs from the CHF patients with hypersplenism (P<0.001). Further, a significant increase in TUNEL(+) EPCs was observed in the CHF patients with hypersplenism after 6 h of stimulated ischemia compared with the control subjects (P<0.001). CONCLUSIONS CHF patients with hypersplenism are susceptible to myocardial remodeling. Increased oxidative stress and endothelial dysfunction caused by excess free plasma hemoglobin and heme may partially explain this causality.
Collapse
Affiliation(s)
- Yong Tang
- Department of Cardiology, Zhongda Hospital Affiliated to Southeast UniversityChina
- Department of Cardiology, The Second Hospital Affiliated to Southeast UniversityChina
| | - Wenbin Lu
- Department of Cardiology, Zhongda Hospital Affiliated to Southeast UniversityChina
- Department of Cardiology, The Second Hospital Affiliated to Southeast UniversityChina
| | - Ziwei Zhang
- Division of Endocrinology, The Drum Tower Hospital Affiliated to Nanjing UniversityChina
| | - Pengfei Zuo
- Department of Cardiology, Zhongda Hospital Affiliated to Southeast UniversityChina
| | - Genshan Ma
- Department of Cardiology, Zhongda Hospital Affiliated to Southeast UniversityChina
| |
Collapse
|